Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced or recurrent non‐small cell lung cancer (NSCLC). They cause immune‐related adverse events (irAEs), but the underlying mechanisms and predictors remain to be fully elucidated. In this retrospective study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Airi, Toyokawa, Gouji, Koutake, Yoshimichi, Kimura, Shigeru, Kawamata, Yosei, Fukuishi, Kazuhisa, Yamazaki, Koji, Takeo, Sadanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327687/
https://www.ncbi.nlm.nih.gov/pubmed/34173724
http://dx.doi.org/10.1111/1759-7714.14063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327687/
https://www.ncbi.nlm.nih.gov/pubmed/34173724
http://dx.doi.org/10.1111/1759-7714.14063

Ejemplares similares